What is LQDA's P/E ratio?

Liquidia Technologies Inc (LQDA) currently trades at a P/E ratio of 114.50.

Liquidia Technologies Inc reports a Return on Equity (ROE) of 20.54%.

What is LQDA's dividend yield?

Liquidia Technologies Inc offers a dividend yield of 0.00%.

What is LQDA's Quality Score?

Our AI rates LQDA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy LQDA?

Our AI Timing Score for LQDA is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does LQDA belong to?

Liquidia Technologies Inc is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

Liquidia Technologies Inc (LQDA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

LQDA AI Analysis Summary

Our AI summary for LQDA: Liquidia Technologies Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 114.50, ROE of 20.54%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LQDA

Liquidia Technologies Inc

USD 84.11

-2.69 (-3.10%) Day Change

Watchlist Portfolio Compare Chart

114.50

P/E

1.65

D/E

20.5%

ROE

5.6%

ROA

0.00%

Div Yield

5.28

PEG

LIQUIDIA TECHNOLOGIES INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 84.11 Price -2.69 (-3.10%) Day Change	NEWS SCORE: 99

LQDA, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.12 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	84.11
PBV / Sector	71.09 / 3.22
Earning Per Share	0.24

PE / Sector	114.50 / 29.79
PEG or PE/Growth / Sector	5.28 / 0.13
Average 1M Daily Value	114.19 M GREAT
Average 1W Daily Value	107.99 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	7.74 / 15.21
NPM Average (%) / Sector	-334.74 / -10.83
NPM Change Average (%) / Sector	-7.79 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	5.55 / 8.15
ROA Average (%) / Sector	-34.03 / 2.87
ROA Change Average (%) / Sector	-23.75 / 112.70
ROE (%) / Sector	20.54 / -1.02 GOOD
ROE Average (%) / Sector	-102.72 / 8.35
ROE Change Average (%) / Sector	36.39 / 385.91 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 08:00:07
Symbol	LQDA
Name	LIQUIDIA TECHNOLOGIES INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	88.93 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	7,718.96 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 419 Davis Drive, Morrisville, NC, United States, 27560

Phone: 919 328 4400

Website: https://www.liquidia.com

Employees: 216

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.